الصفحة 1 من عند 16 النتائج
The present invention is concerned with indolin-2-one derivatives of general formula
##STR00002## wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from
##STR00003## or the amine group --NR.sup.1R.sup.2 may form together with two neighboring carbon atoms
The present invention is concerned with indolin-2-one derivatives of general formula
##STR00002## wherein A is phenyl or a five or six membered heteroaryl group, containing one or two N atoms, selected from
##STR00003## or the amide group --C(O)--NR.sup.1R.sup.2 may form together with two
The present invention is concerned with indolin-2-one derivatives of general formula
##STR00004## wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from
##STR00005## or the oxygen atom may form together with two neighboring carbon atoms from the group A
The present invention is concerned with indolin-2-one derivatives of general formula
##STR00004## wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from
##STR00005## R.sup.1 is S(O).sub.2lower alkyl, S(O).sub.2NR.sup.4R.sup.5, S(O).sub.2cycloalkyl,
BACKGROUND OF THE INVENTION
The market for neuroscience and women's health drugs has been moving towards the use of dual serotonin and norepinephrine reuptake inhibitors (SNRI) for first line treatment of various indications, as evidenced by the recent development of SNRI's such as Venlafaxine and
BACKGROUND OF THE INVENTION
The market for neuroscience and women's health drugs has been moving towards the use of dual serotonin and norepinephrine reuptake inhibitors (SNRI) for first line treatment of various indications, as evidenced by the recent development of SNRI's such as Venlafaxine and
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels in the central nervous system (CNS) and the peripheral nervous system (PNS). The nAChRs serve a wide range of physiological functions, and have been implicated in a number of pathological
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels in the central nervous system (CNS) and the peripheral nervous system (PNS). The nAChRs serve a wide range of physiological functions, and have been implicated in a number of pathological
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
BACKGROUND OF THE INVENTION
The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological effect via two types of cholinergic receptors; the muscarinic ACh receptors and the nicotinic ACh receptors. As it is well established that muscarinic ACh receptors dominate quantitatively
FIELD OF THE INVENTION
The present invention relates to novel methods of use of specific cytokine antagonists for the treatment of neuropsychiatric and neurological disorders in humans. More particularly, these cytokine antagonists are used in a new treatment of neuropsychiatric and neurologic
FIELD OF THE INVENTION
The present invention relates to novel methods of use of specific cytokine antagonists for the treatment of neuropsychiatric and neurological disorders in humans. More particularly, these cytokine antagonists are used in a new treatment of neuropsychiatric and neurologic